Caydan Capital Partners Leads Venture Financing for TecTraum

Investment supports TecTraum's advancement of pro2cool®, a breakthrough medical device platform designed to treat concussions through non-invasive cooling therapy

‍

BOSTON, MA - Caydan Capital Partners today announced that it has led a $965,000 venture financing for TecTraum Inc., a medical device company developing pro2cool®, a first-of-its-kind point-of-care treatment platform for concussions.

‍

TecTraum's flagship technology, pro2cool®, is a non-invasive hypothermic therapy device designed to deliver localized cooling to the head and neck following a concussion. The system is intended to reduce the severity of concussion symptoms and support patients in returning to their pre-injury baseline sooner. pro2cool® has received Breakthrough Device designation from the U.S. Food and Drug Administration and has been evaluated in a large multisite clinical trial focused on adolescent athletes with concussion.

‍

Caydan's investment reflects its focus on partnering with high-potential companies developing breakthrough technologies in large and underserved markets. Through the financing, Caydan is supporting TecTraum's continued advancement of pro2cool® as the company works to address a significant unmet need in concussion care.

‍

"TecTraum represents exactly the type of innovative, mission-driven company Caydan seeks to support," said Rick Waldo, Managing Partner at Caydan Capital Partners. "Concussion treatment remains a significant unmet need across athletics, military, and broader healthcare settings, and pro2cool® offers a differentiated approach with the potential to meaningfully improve patient outcomes. We are proud to partner with John Zak and the TecTraum team as they continue advancing this important technology."

‍

Concussions remain a major challenge across youth, collegiate, professional, and military settings, with limited treatment options available beyond rest and symptom management. TecTraum, led by President John Zak, is working to provide clinicians, athletic trainers, and care teams with a safe, easy-to-use treatment platform that can be deployed in a variety of care environments.

‍

The financing underscores Caydan Capital Partners' commitment to backing companies with strong leadership teams, differentiated technologies, and the potential to create meaningful impact in their markets. For TecTraum, the investment represents an important step in the continued development and commercialization pathway for pro2cool®.

‍

About TecTraum Inc.

TecTraum Inc. is a medical device company dedicated to advancing concussion treatment through its flagship technology, pro2cool®. The pro2cool® system is a non-invasive hypothermic therapy device designed to provide localized cooling to the head and neck following concussion, with the goal of reducing symptoms and improving recovery outcomes.

‍

About Caydan Capital Partners

Caydan Capital Partners is a leading private equity firm focused on partnering with growth-oriented, North American companies in the lower middle market. Caydan offers its investors access to the historically inaccessible lower middle market through a unique combination of three diversified investment strategies across private equity, public equity, and venture capital. For more information, please visit https://www.caydancapital.com/.

‍